CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Paradigm Biopharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Paradigm Biopharmaceuticals Ltd
Level 15, 500 Collins St
Phone: +61 396295566p:+61 396295566 MELBOURNE, VIC  3000  Australia Ticker: PARPAR
Business Summary
Paradigm Biopharmaceuticals Limited is a late-stage drug development company. It is engaged in researching and developing therapeutic products for human use. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS clears cellular and tissue accumulation of GAGs. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses (MPS); treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director PaulRennie 11/22/2022 5/2/2014
Interim Chief Financial Officer, Company Secretary Abby M.Niven 3/3/2023 3/3/2023
Executive Director, Chief Medical Officer DonnaSkerrett 7/1/2022 7/3/2020
Non-Executive Director Matthew J.Fry 3/4/2024 3/4/2024
Non-Executive Independent Director AmosMeltzer 12/9/2020 12/9/2020

General Information
Outstanding Shares: 351,495,841 (As of 12/31/2023)
Shareholders: 14,072
Stock Exchange: ASX
Fax Number: +61 396295466


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024